Thermo Fisher Scientific will spend more than $600 million in capital investments to expand its bioprocessing produ ction capabilities through 2022, according to the company. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions. Source: Genetic Engineering News 10/3/2021